Drug Database
NI

nitroglycerin (Millisrol Tape)

✓ Approved

Nippon Kayaku Co.,Ltd. · Small Molecule · Small Molecule

What is nitroglycerin?

nitroglycerin is a small molecule developed by Nippon Kayaku Co.,Ltd.. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesMillisrol Tape
CompanyNippon Kayaku Co.,Ltd.
Drug ClassSmall Molecule
RouteTransdermal
StatusApproved
Sources: ClinicalTrials.gov, Nippon Kayaku Co.,Ltd.

Therapeutic Indications

nitroglycerin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersAngina pectoris✓ Approved

Related Research Articles

PubMedChemistryOpen2026-11-12

Optimized Roflumilast Ethosomal Gel for Enhanced Transdermal Therapy in Atopic Dermatitis: An In Vitro Study.

Mehmood Yasir Y, Rizvi Syeda Momena SM, Javed Atika A, Siddique Rida R et al.

This study evaluated a transdermal drug delivery system using roflumilast (RT)-loaded ethosomal gel for the topical treatment of inflammatory skin disorders. RT-loaded ethosomes were prepared using the cold method and incorporated into a topical gel. Eight formulations were developed and optimized using a Design of Experiments approach to investigate the effects of formulation variables on drug entrapment and performance. Among them, RT-5 was selected as the optimized formulation and evaluated for physicochemical properties, stability, microbiological quality, drug release, and transdermal permeation. RT-5 exhibited suitable topical characteristics, including a pH of 5.3-5.5, viscosity of 90-91 cP, and good spreadability. In vitro diffusion studies at pH 5.5 showed 25.5% ± 3% drug release within the first hour compared with 5.2% ± 2% from the commercial cream. Moreover, RT-5 achieved cumulative drug penetration of 99.34% after 12 h, demonstrating enhanced transdermal delivery. Stability studies showed that the formulation maintained acceptable pH, viscosity, consistency, and appearance for 6 months under recommended storage conditions and at least 3 months under accelerated conditions. Microbiological testing revealed no detectable bacterial growth. The outcome of this work showed that RT-5 demonstrated satisfactory stability, quality, and improved transdermal delivery of roflumilast.

PMID 43016129
Read full article →
PubMedJournal of the American Heart Association2026-11-12

Safety and Efficacy of Topical Nitroglycerin for Radial Artery Dilation (The RADial Trial): A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Ullah Waqas W, Janga Chaitra C, Foster Michael M, Nugooru Sudeep S et al.

Transradial coronary catheterization is associated with a reduced risk of bleeding and vascular complications. Prior studies have evaluated nitroglycerin to improve transradial access by vasodilating the radial artery, but the optimal route of administration for preprocedural arterial dilation remains unclear. In the RADial Trial (Radial Artery Dilatation Trial) patients undergoing transradial coronary catheterization were randomized in a double-blind fashion to receive either a placebo or topical nitroglycerin ointment (nitropaste). The primary outcome was the mean change in radial artery dimensions, assessed using paired t tests. Categorical outcomes were analyzed using odds ratio (OR) with 95% CI. A total of 260 patients (130 placebo, 130 nitroglycerin) were enrolled. Nitropaste significantly increased the mean diameter (2.65±0.6 versus 2.48±0.6 mm), circumference (8.37±1.63 versus 7.77±1.66) and cross-sectional area (5.63±2.28 versus 4.94±2.0 mm) of the radial artery, whereas no significant difference was observed in the placebo arm. Nitropaste was associated with a significant reduction in the number of skin punctures and risk of vasospasm (OR 0.34 [95% CI, 0.13-0.91], P=0.04). There was no significant difference between nitropaste and placebo groups in the odds of hematoma (OR, 0.32 [95% CI, 0.03-3.1], P=0.61), crossover to femoral access (OR, 2.29 [95% CI, 0.9-5.8], P=0.12), need for ultrasound-guided access (OR, 0.39 [95% CI, 0.13-1.15], P=0.13), and hypotension or headache (OR, 1.5 [95% CI, 0.24-9.2], P=1.0). Preprocedural administration of nitropaste significantly increases radial artery size and reduces the risk of vasospasm without causing headache or hypotension. https://clinicaltrials.gov/study/NCT05239013.

PMID 43017937
Read full article →
PubMedThe journal of headache and pain2026-11-12

Salience-limbic-cerebellar network reconfiguration during nitroglycerin-triggered cluster headache attacks.

Wei Diana Y DY, Zelaya Fernando O FO, O'Daly Owen O, Goadsby Peter J PJ

Cluster headache is one of the most painful known disorders. Cluster headache sufferers compare the extreme unilateral pain to labour pains and gunshot wounds. Given the many logistical challenges of capturing spontaneous cluster headache attacks, only a handful of neuroimaging studies have successfully captured such attacks. Intravenous nitroglycerin (NTG) reliably induces cluster headache attacks in a controlled setting, thereby enabling investigation of resting-state functional connectivity during the attack stage. Cluster headache patients aged 18-60 years were recruited from both the population and tertiary headache clinics. Consented participants received either 0.5 µg/kg/min NTG or placebo infusion for 20 min. Structural T1, T2 and FLAIR sequences and resting state blood oxygen level dependent contrast (BOLD) time series were obtained at baseline (pre-infusion) and during headache. A total of 16 paired headache (NTG-infusion) and placebo scans were analysed. The functional connectivity was assessed for three pre-determined seeds: thalamus, ACC and insula. A two-factor (time and treatment), repeated measures 2 × 2 ANOVA model was used to assess main effects and interactions. Significant changes in functional connectivity between the contralateral amygdala (T = 3.47, peak connectivity change at 30, 0, -20, P < 0.001), and hippocampus (T = 4.33, peak connectivity change at 28, -8, -20, P < 0.001) and ipsilateral cerebellum culmen (T = 5.13, peak connectivity change at -14, -30, -18, P < 0.001), with respect to the anterior insula ipsilateral to the pain side. These findings suggest reconfiguration of salience, limbic, cerebellar and default mode networks during the cluster headache attack state and implicate the cerebellum in trigeminal nociceptive processing.

PMID 43015608
Read full article →
PubMedLab on a chip2026-11-12

A decellularized skin matrix/GelMA epidermal-dermal skin-on-a-chip for transdermal assessment and modular skin-liver modeling.

Wang Jiashu J, Wu Guohua G, Du Qijun Q, Wu Di D et al.

Many three-dimensional (3D) skin equivalents are established separately from microfluidic devices and are not readily compatible with downstream organ integration. We developed a microfluidic epidermal-dermal skin model using a composite hydrogel comprising a decellularized skin matrix (DSM) and gelatin methacryloyl (GelMA), termed G-DSM. Combined with interstitial perfusion and air-liquid interface (ALI) culture, the platform supported the establishment of a day-7 construct containing epidermal and dermal compartments. The construct expressed keratin 14 (K14), keratin 10 (K10), claudin-1, and fibronectin and showed lower apparent permeability to BSA and benzoic acid than the dermal-only construct, together with a water vapor transmission rate close to that of native skin. Functionally, the model exhibited concentration-dependent PICP and fibronectin responses to VC and retinol, with an intermediate-concentration combination producing greater responses than the corresponding single-agent treatments. The model also distinguished concentration-dependent local cytotoxicity among five selected chemicals and generated a study-specific exploratory ranking. Coupling the skin construct to a downstream liver compartment showed that the transdermal route reduced liver-inlet APAP exposure, while approximately AUC-matched comparisons indicated that the route-associated differences in ROS and viability were largely exposure-dependent.

PMID 43016207
Read full article →
PubMed3 Biotech2026-11-12

Next-generation microneedle platforms for transdermal therapeutics: a comprehensive review of innovations and challenges.

Alruwaili Nabil K NK

Microneedle patches (MNPs) are becoming promising new opportunities to replace traditional methods of drug delivery like oral, topical, and injectable routes, due to their minimally invasive nature and their potential to deliver drugs transdermally. Compared to oral formulations, MNPs bypass gastrointestinal degradation and hepatic first-pass metabolism, thereby enhancing systemic bioavailability and therapeutic effects. These systems use micron-sized solid or hollow needles that can penetrate the stratum corneum, the major barrier to cutaneous penetration. MNPs can be used to deliver therapeutic agents directly to the viable epidermis and systemic circulation by forming transient microchannels in the skin. Recent developments in the field of engineering, such as 3D printing technologies, dissolving and hydrogel-forming polymers, and smart stimuli-responsive systems, have greatly broadened the therapeutic applications of the microneedle platform beyond passive drug diffusion. These technologies enable regulated, programmed, and feedback-controlled drug delivery, making MNPs the future of transdermal delivery for vaccines, biologics, metabolic disease, oncology, and precision medicine. This review critically and comparatively analyzes the strategies of microneedle design, fabrication techniques, drug-loading approaches, and clinical uses. Special attention is given to the barriers to translation, such as mechanical strength, dose reproducibility, scale production, sterilization, regulatory status as combination products, and long-term safety. In addition, new trends, including nano-integrated theranostic microneedles, closed-loop glucose-responsive systems, and AI-enabled personalized fabrication, are mentioned to map out a path towards clinical adoption. This review will establish the future of the microneedle-based drug delivery systems by combining engineering innovation with translational insight.

PMID 43016851
Read full article →
PubMedThe Canadian journal of urology2026-11-12

Transdermal estradiol for prostate cancer: how do patients compare it to other options for androgen deprivation therapy?

Sears Carly C, Wassersug Richard R, Brown Eric E, Schellhammer Paul P et al.

The PATCH/STAMPEDE trial [NCT00303784] in the UK has established that transdermal estradiol (tE2) offers equally effective cancer control for systemic prostate cancer (PCa) as standard androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone agonists alone or combined with androgen receptor pathway inhibitors. ADT with tE2 provides significantly better quality of life. However, there are no tE2 products specifically licensed for PCa patients and little evidence on whether PCa patients would be interested in using tE2 for ADT compared to other ADT options. Given that background, we used an online survey to explore PCa patients' reservations versus enthusiasm for tE2 as an option for ADT compared to standard ADT. We also assessed patient preferences for various forms of tE2 administration. The objective of this exploratory study was therefore to assess PCa patients' interest in and concerns about alternative forms of ADT. From 13 March-26 May 2025, we conducted a cross-sectional online survey of men diagnosed with PCa, who were accrued via PCa support organizations in Canada and the USA. The survey included both multiple-choice and an open-ended question. Eight hundred and twenty-seven PCa patients completed the survey: 45% from the USA, 41% from Canada, 14% from outside North America. Overall, interest in tE2 was high, with >95% of patients wanting tE2 to be a standard of care option for ADT in their country. In terms of positive versus negative comments on ADT, out of 86 comments on standard ADT, 80% were negative. In contrast, out of 23 comments on tE2, none was negative. The great majority (72%) of participants were willing to pay for tE2 off-label and even more (76%) said they would be willing to consult with more than one physician for an off-label prescription. The highest interest in tE2 came from PCa patients who have never been on ADT. Older patients had significantly less concern about gynecomastia, but this did not predict interest in tE2. About 2.8 times more men reported a preference for daily topical tE2 cream/gel products versus multiple tE2 patches changed twice a week. Our survey establishes that men with PCa believe that tE2 products should be among the standard of care options for ADT and that tE2 side effects are more manageable than those of standard ADT drugs. For administering E2, patients preferred daily topical application of a gel or cream to wearing multiple patches.

PMID 43016020
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about nitroglycerin